..engaged Fruci & Associates as its auditors as it moves forward to complete its audits and reviews of its financials to bring the company back to current status.
SEC filed.. penalty of $500,000 for the party that breaches terms of the binding LOI. Lans Holdings Successfully Completes Due Diligence of Global Stem Cells Group https://www.otcmarkets.com/stock/LAHO/news
Global Stem Cells Group CEO Benito Novas is driven by his passion for helping physicians and scientists change the world through stem cell medicine. Dedicated to creating critical organizational systems that ensure success, he is an expert in the field of specialized marketing focused on Biotechnology, Life Sciences, and Healthcare development.
We’re positioning Adimarket to become the largest e-commerce marketplace for all things regenerative medicine,” says Benito Novas, founder and CEO of Global Stem Cells Group.
US health..spending increased 5.8%..3.2 Trillion which is also expected to impel the growth of stem Cell and regenerative medicine market in the North America. U.S. is the prominent market driving the growth in the region.
..North America is slated to account for a leading share of 39.7% by 2024 in the stem cell and regenerative medicine market. The growth in the region can be attributed to presence of well-established healthcare industry along with expanded funding from the governments organizations.
Adimarket announce agreement.. N-Biotek to offer the Total Solution highly manipulated stem cell culture expansion lab, complete with equipment, training, facilities, stem cell processing center, clean rooms, project plan and more- a total turnkey lab solution for emerging stem cell businesses and industry professionals. The announcement marks a new chapter in GSCG’s ongoing expansion, and commitment to bring stem cell therapies..
..Until now, Admarket has been GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering basic tools and products to facilitate in-office stem cell procedures. However, through N-Biotek, Adimarket now offers the Total Solution labs and all the accoutrements. From planning to building the facility, to training and consultation, Total Solution users are equipped in every way possible to walk in and begin using their fully-equipped biotechnology lab in short order.
GSCG established.. alliance.. HANK Bioengineering..Shenzhen, China
..Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration.. Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.
..Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.
ZhangM3
..disease progression at 3 months after treatment was 18.8%, 50.0% and 31.2%, respectively. The total follow-up period was 2-12 months. The median progression-free survival from treatment was 7.5 months. This is the first study on the benefits of HANK cell immunotherapy for hepatic carcinoma These encouraging preliminary observations imply that HANK cell immunotherapy is safe, can improve the immune function of patients with liver cancer, and may even reduce the rate of tumor metastasis and recurrence...
$600 BILLION BOFA..WALL STREET'S MAJOR INVESTMENT BANKS..
..One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025..
Regenerative medicine will dramatically alter the U.S. healthcare industry
..Because of the economic potential of this industry (the worldwide market for regenerative medicine is conservatively estimated to be $500 billion..
An example of some conditions and diseases that could be easily cured by regenerative medicine and their current cost of treatmentt include:
250,000 patients receive heart valves, at a cost of $27 billion annually 950,000 people die of heart disease or stroke, at a cost of $351 billion annually(8) 17 million patients with diabetes, at a cost of $132 billion annually
..By doing so, we can make tissue and organ failure a relic of the past by 2020.
Interagency Federal Working Group on Regenerative Medicine
Chair Howard Zucker, MD, JD Deputy Assistant Secretary for Health U.S. Department of Health and Human Services National Institutes of Health Donna Dean, PhD Colleen Guay-Broder, MPH Eleni Kousvelari, PhD Christine Kelley, PhD John Watson, PhD Josh Zimmerberg, PhD
Food and Drug Administration Charles Durfor, PhD Donald Fink, PhD Joyce Frey, PhD Jesse Goodman, MD Darin Weber, PhD Celia Witten, PhD
The Smart Money Is Piling Into Regenerative Medicine
Progressive Approval Could Be a Game Changer for RM Investing in Regenerative Medicine
The Goldman report discusses Samumed, a private RM company. With $300 million in funding, [b[color=red]]it’s valued at a staggering $12 billion[/color]. Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.
Goldman Sachs defines regenerative medicine as approaches that grow cells or tissue from stem cells, treatments that promote regeneration, or transplants using organs or tissue grown outside the body.
Goldman Sachs highlighted..$12 billion private biotech startup that wants to regenerate hair, skin, bones, and joints, and Unity Biotechnology, which is working on treatments that act on senescent cells.
Money is pouring in to a hot new area of science that could change the way we think about aging
.."We believe companies backed by academic pioneers ... or those with novel platforms ... are likely to garner the largest investments and valuations," the report said.
The Shiller P/E is amore reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
Pfizer and Allergan Merge in $160 Billion Deal to Become New Behemoth in the Drug World
What Does Pfizer Have to do with the World of Stem Cells?
Most people would not call Pfizer a stem cell company, much less a cell therapy company, a regenerative medicine company, or even a biotech company. Pfizer is viewed as a “classic and traditional” pharmaceutical company, best known for its blockbuster sales of drugs, such as Lipitor and Viagra. While Pfizer is largely a drug company, the company has expressed periodic interest in the stem cell sector.
Executive Committee and Board Member of the Coral Gables Chamber of Commerce, former President of the Rotary Club of Brickell, current President of BNI Coral Gables, past president of his home owner’s association, and supporter of many fundraisers devoted to the community. Eric also regularly teaches other lawyers for their continuing legal education, presents to The American Immigration Lawyers Association, and more.
Washington College of Law. Juris Doctor (JD) Kogod School of Business. Masters in Business Administration (MBA) Southern Methodist University. Bachelor of Arts (BA). Sigma Chi Fraternity Jesuit College Preparatory School, Dallas
Bar Admissions:
State of New York State of Maryland District of Columbia State of Florida Federal District Court for the Southern District of Florida Federal District Court for Maryland U.S. Tax Court
CLE Lecture: “The New Tax Rules for Mergers and Acquisitions.” June, 2018
..Stem cells are jacks of all trades, capable of alleviatingthe consequences of such diverse pathologies as heart attacks, strokes and cancer. ..In a new study, Yale researchers succeeded in doing so, opening the door to new stem cell-inspired, cell-free treatments for the effects of a heart attack. https://phys.org/news/2019-07-decoding-cells-stem-potential.html
“Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth,” says the US National Institutes of Health. “In many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive
Market cap: $2.09 billion; current share price: $24.25 Market cap: $226.15 Million; current share price: $1.83 Market cap: $161.84 million; current share price: $1.47 Market cap: $267.60 million; current share price: $19.10 Market cap: $392.71 million; current share price: $11.25 Market cap: $64.63 million; current share price: $3.43 Market cap: $54.74 million; current share price: $5.78 Market cap: $11.05 million; current share price: $0.31 Market cap: $29.88 million; current share price: $2.75 Market cap: $28.40 million; current share price: $1.30 https://investingnews.com/daily/life-science-investing/genetics-investing/top-stem-cell-nasdaq/
CONSUMER REPORT..stem cells market. a whole lot of demand
..After receiving a personal invitation from President Susumu Takayangi MD, Global Stem Cells Group and its Korean biotechnology partner, N-Biotek, participated in the 23rd Congress of the International Society of Aesthetic Plastic Surgeons that took place this October in Kyoto.
The Congress brought together an expert panel for a series of lectures and discussions that hope to provide solutions and create new techniques in the coming years to be applied in plastic and reconstructive surgery. Influential scientific and clinical experts stood together and evaluated the state of research and clinical application.
The keynote speaker in the conference was the Nobel Laureate Shinja Yamanaka. Dr Yamanaka won the award on 2012 for his creation of induced pluripotential stem cells. Yamanaka addressed among other things the importance of the regenerative medicine field opening a new frontier for the treatment of chronic degenerative conditions.
..Both companies, as leaders of the industry, launched their new Turnkey Solution, a compact and cohesive laboratory as a concept for physicians’ offices, and the new Progenikine Kit, an enzyme based closed system for isolation of adipose derived stem cells. To learn more, visit the Global Stem Cells Group website, www.stemcellsgroup.com.
..Doctors at St. Jude Children's Research Hospital used Mustang-developed "genetic surgery" to restore the broken immune systems of these eight infants afflicted with the disease. Stansberry Innovations Report editor Christian Olsen explained how this works in a private note on Friday...
First they extracted stem cells from a patient, then used a modified HIV virus to deliver and insert a healthy IL2RN gene into the stem cells, and then infused the modified stem cells back into the patient.
To get the patient ready to accept the changed cells, they were given a low dose of chemotherapy to prime the bone marrow. The bone marrow is what will produce blood cells from the genetically corrected stem cells and... Voila! Healthy immune system.
This may sound like science fiction.But it's not...
Gene therapy and editing is a real and growing trend you will hear about much more over the next several years. More from Christian...
This is real personalized medicine, which is the "Holy Grail." Cells were taken from a patient and used to create the treatment.
There is no doubt we are on the cusp of more of these success stories but, remember, at this stage we (at best) have a curative potential for "bubble boy" disease. There has to be more testing, but the news is incredibly promising.
So, MBIO shot up because it's the lead dog in this treatment tech, since it licensed it to treat patients at St. Jude.
One of the greatest challenges of the 21st century is disease associated with ageing. Cancer, neurodegeneration and heart disease are all major causes of death and have an enormous impact on quality of life.
..Over recent years, a revolution in biology has meant that effective regenerative medicine, using stem cells to replace and repair damaged tissue is now on the horizon. Naturally occurring ‘immortal’ stem cells are present in all tissues of the body and act to replace loss of cells in tissues with rapid turnover, for example in the skin, blood or intestine, or to repair damage as in wound healing.
..The new biotech initiative whose board includes former Apple CEO John Sculley, ex-FDA commissioner Andrew Von Eschenbach and founder of Alphabet’s venture capital arm Bill Maris, is built around the idea that stem cells found in postpartum human placentas are ideal for regenerating damaged and aged tissue
..“There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease,”
The most successful stem cell therapy—bone marrow transplant—has been around for more than 40 years. Johns Hopkins researchers played an integral role in establishing the methods for how bone marrow transplants are done
..Our mission is to find cures for human diseases.
The Harvard community and the greater Boston area are home to the largest concentration of biomedical researchers in the world. This allows our network of over 1,000 scientists, from across Harvard and its eight affiliated hospitals, to advance stem cell biology and translational me
Adimarket, has announced an agreement with biotechnology company Alolotl Biologix ..healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.
Human allograft under FDA regulation 21 CFR Part 1271 ..Immune privileged with anti-inflammatory and anti-bacterial properties
$LAHO..US health..spending increased 5.8% to..USD 3.2 Trillion trillion which is also expected to impel the growth of stem Cell and regenerative medicine market in the North America. U.S. is the prominent market driving the growth in the region.
..North America is slated to account for a leading share of 39.7% by 2024 in the stem cell and regenerative medicine market. The growth in the region can be attributed to presence of well-established healthcare industry along with expanded funding from the governments organizations.
Who Wants To Live Forever?..The Super-Rich, That's Who (And Most Everyone Else)
..Not only do many of the super-rich want immortality, but a good number of them are doing something about it. The likes of Sergey Brin, co-founder of Google, Larry Ellison, Co-founder of Oracle, and investor Peter Thiel are all putting money into ventures that are focused on extending the human life span.
..Hacking our DNA is another approach being taken. Our ability to use stem cells to cure disease is becoming increasingly an opportunity. Very possibly using stem cell technology, as well as modifications to our DNA, can result in significantly longer fruitful lives.
..Global Stem Cells Group Teams With CordónVida Servet Stem Cell Bank and Clinic to Organize the First International Symposium on Stem Cells and Regenerative Medicine
On the immortality of stem cells University of Cologne
Summary: Stem cells are considered to be immortal in culture and, therefore, of great interest for aging research. This immortality is regulated by increased proteostasis, which controls the quality of proteins. A team of researchers found a link between increased proteostasis and immortality of human embryonic stem cells
The cell is the minimal body’s representation, it is the basic unit for the living species where all the vital functions happen such as respiration, nutrition, and reproduction. The STEM CELL is a special cell that normally circulates in the body, responsible for regenerating naturally the deteriorating organs. This treatment seeks for the stem cells to differentiate or become healthy cells from damaged or defective tissue to improve the function of the diseased organ.
Cellgenic Catalogue! $2100.00* · Brand: ADIMarket Cellgenic Pure contains 10 millions of live nucleated cells that exert an anti inflammatory and immunomodulatory effect that aids in optimizing
The cell is the minimal body’s representation, it is the basic unit for the living species where all the vital functions happen such as respiration, nutrition, and reproduction. The STEM CELL is a special cell that normally circulates in the body, responsible for regenerating naturally the deteriorating organs. This treatment seeks for the stem cells to differentiate or become healthy cells from damaged or defective tissue to improve the function of the diseased organ.
http://cellgenic.com/ Cellgenic Catalogue! $2100.00* · Brand: ADIMarket Cellgenic Pure contains 10 millions of live nucleated cells that exert an anti inflammatory and immunomodulatory effect that aids in optimizing $2,382.00 Cellgenic Amniotic Fluid-Human placental Derived
LAHO!..CEO Announces..New Stem Cell Center in Valencia, Spain
..“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.” https://www.otcmarkets.com/stock/LAHO/news/story?e&id=1376239
NASA and Techshot Trying To 3D Print Organs In Space
..Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, announces it will represent CELLLINK 3D Bioprinting Technology in Latin America. CELLINK is the world’s first company biotech company to market bioinks for 3D bioprinting of human organs and tissue. http://www.stemcellsgroup.com/tag/3d-bioprinnting/
.. rise in geriatric population, technological improvements for manufacturing customized Material Types, and growth in focus on R&D investment. Also, the increase in usage of 3D printing in cosmetic surgeries is anticipated to increase the market growth during the forecast period further.
Global Stem Cells Group CEO Benito Novas is driven by his passion for helping physicians and scientists change the world through stem cell medicine. Dedicated to creating critical organizational systems that ensure success, he is an expert in the field of specialized marketing focused on Biotechnology, Life Sciences, and Healthcare development. http://www.stemcellsgroup.com/management/
Global Stem Cells Group’s Benito Novas Announces Agreement with Clinica Planas
..The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
..Bioheart, Inc. (otcqb:BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico. The two companies have successfully treated their first congestive heart failure patient at the new clinical site last week using Bioheart's AdipoCell (adipose derived stem cells).
Global Stem Cells Group to Host Stem Cells and Regenerative ... ISSCA Physicians looking for new alternatives to improve the quality of life of their patients through emerging regenerative medicine protocols..
“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.”
In opening the new center, the GSCG has signed an agreement with Dra. Laura Maria Caicedo, medical director of the Instituto Valenciano MEDEC (https://medec.es/conoce-medec/#equipoMedico). Dr. Caicedo is a specialist on hair loss with an interest in delivering stem cell based treatments to her patients and others in Valencia.
J. Victor Garcia Gimenez, M.D. is president of Therapeutic Confrontations (CONFTERA), is a specialist in orthopedic surgery and practices cosmetic medicine and surgery, anti-aging medicine, and aesthetic therapies in Barcelona, Spain. http://stemcellcenter.net/centers/spain/barcelona/barcelona-spain/\
Aesthetic Marketing Group Announces the First International Meeting on Marketing in Aesthetic Medicine
GSCG..ISSCA Reaches Agreement with Belgium’s Churchill Aesthetic Center
..The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and... Friday, June 21st 2019, 12:32 PM CDT The innovative new center will provide training in regenerative medicine for doctors located in Belgium and France. ..We look forward to ISSCA’s exciting new partnership with Belgium’s Churchill Aesthetic Center and the possibilities it brings in delivering safe and effective regenerative medicine treatment options to more patients across the globe,” said Benito Novas, CEO of the Global Stem Cells Group.
....The cutting-edge facility will be equipped by Adimarket, LLC, a subsidiary of the Global Stem Cells Group. Adimarket will outfit the center with equipment and supplies designed to not only teach doctors about the latest protocols in regenerative medicine but also to treat patients suffering from degenerative diseases and sports injuries. Physicians training at the facility will have access to the proven expertise of ISSCA’s global network and training protocols. http://www.stemcellsgroup.com/issca-reaches-agreement-with-belgiums-churchill-aesthetic-center/
Daeyong Kim, Ph.D. is an internationally recognized health educator, and CEO of N-Biotek, Inc, a preeminent manufacturer of biomedical and laboratory equipment. N-Biotek is a leader of stem cell technologies, providing solutions for providers worldwide.
..Dr. Zhang is an accomplished scientist, microbiologist and virologist who has worked extensively in the U.S. for the CDC, the National Institutes of Health (NIH) and the US Food and Drug Administration in various research positions, including senior associate at the National Research Center. A Chinese-American, Dr. Zhang received the Award for Scientific Achievement from the FDA
..Al Sears, M.D. often referred to as "America’s #1 anti-aging doctor," is the director of the world renowned Sears Institute for Anti-aging Medicine. Dr. Sears has published 35 books and reports on health and wellness, and has millions of loyal readers in 163 countries. Dr. Sears has been featured on ABC News, CNN and ESPN. He was one of the first specialists to be board-certified by the American Academy of Anti-Aging Medicine (A4M).
Dr. Feinerman offers stem cell treatments for a variety of disorders and diseases. He earned his medical degree from New York Medical College in 1954. Dr. Feinerman is affiliated with Long Island College Hospital in New York and Mayo Clinic in Rochester, Minnesota.
Dr. Feinerman is a member of the Society of Apheresis, Society of Bone Marrow Blood Transplantation, and the International Society for Cellular Therapy, the Society for Cranial Transplantation and Brain Repair and the Society for Cardiac Translational Therapy.
We pledge to adhere to the highest standards of integrity on behalf of our customers, our stockholders, and the world. We have created the optimal corporate structure to realize Global Stem Cell Group’s long-term potential, and we have established the appropriate financial controls and management oversight of our internal processes.
$LAHO GSCG..REPRESENTING 46% MARKET GROWTH IN THERAPY REGENERATION, 3D PRINTING, COSMETIC, MEDICAL DEVICES, PROVIDER CONSULTATION, LABS. BOFA ESTIMATES $600 BILLION TARGET, USDHHS CONSERVATIVE ESTIMATE $500 billion AND IMPRESSIVE 7300% VENTURE CAPITAL INVESTMENT GROWTH. GOLDMAN SACH'S, BILLIONAIRES PURING MONEY INTO STEM CELLS. GSCG.. EACH DIVISION OF GSCG COULD RUN TO PENNIES..COMBINED IN TRILLINO DOLLAR INDUSTRY?
..engaged Fruci & Associates as its auditors as it moves forward to complete its audits and reviews of its financials to bring the company back to current status.
SEC filed.. penalty of $500,000 for the party that breaches terms of the binding LOI. Lans Holdings Successfully Completes Due Diligence of Global Stem Cells Group https://www.otcmarkets.com/stock/LAHO/news
We’re positioning Adimarket to become the largest e-commerce marketplace for all things regenerative medicine,” says Benito Novas, founder and CEO of Global Stem Cells Group.
US health..spending increased 5.8%..3.2 Trillion which is also expected to impel the growth of stem Cell and regenerative medicine market in the North America. U.S. is the prominent market driving the growth in the region.
..North America is slated to account for a leading share of 39.7% by 2024 in the stem cell and regenerative medicine market. The growth in the region can be attributed to presence of well-established healthcare industry along with expanded funding from the governments organizations.
Adimarket announce agreement.. N-Biotek to offer the Total Solution highly manipulated stem cell culture expansion lab, complete with equipment, training, facilities, stem cell processing center, clean rooms, project plan and more- a total turnkey lab solution for emerging stem cell businesses and industry professionals. The announcement marks a new chapter in GSCG’s ongoing expansion, and commitment to bring stem cell therapies..
..Until now, Admarket has been GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering basic tools and products to facilitate in-office stem cell procedures. However, through N-Biotek, Adimarket now offers the Total Solution labs and all the accoutrements. From planning to building the facility, to training and consultation, Total Solution users are equipped in every way possible to walk in and begin using their fully-equipped biotechnology lab in short order.
GSCG established.. alliance.. HANK Bioengineering..Shenzhen, China
..Shenzhen HANK is a biotechnology company established in 2013 by Zhang, an award-winning scientist, microbiologist and virologist, to integrate research, development, production, and sales of biomedical products. Zhang worked at the U.S. Centers for Disease Control from 1991 to 1993, the U.S. National Institute of Health (NIH) from 1993 to 1994, and the U.S. Food and Drug Administration.. Scientific Achievement Award from the USFDA for outstanding achievement in natural killer (NK) cell research, and holds numerous awards for his work in the fields of HIV, HCV, West Nile virus, Japanese encephalitis virus, and quality performance.
..Dr. Zhang expanded on his work in stem cell research and development by launching HANK Bioengineering Co. Ltd. in Shenzhen, China. HANK is a 4,300 square foot (400 square meters) CFDA certified cGMP facility affiliated with HANK Bioengineering Institute’s Cell Biology and Molecular Immunology Laboratories. HANK has established close collaborations with more than five hospitals in China for clinical applications of its cell therapy products.
Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.
ZhangM3
..disease progression at 3 months after treatment was 18.8%, 50.0% and 31.2%, respectively. The total follow-up period was 2-12 months. The median progression-free survival from treatment was 7.5 months. This is the first study on the benefits of HANK cell immunotherapy for hepatic carcinoma These encouraging preliminary observations imply that HANK cell immunotherapy is safe, can improve the immune function of patients with liver cancer, and may even reduce the rate of tumor metastasis and recurrence...
Welcome to the Global Stem Cells Group website! GSCG is a group of companies, each dedicated to facilitating stem cell research and medicine.
Global Stem Cells Group was founded in 2010 by Benito Novas, an entrepreneur who became intrigued by advancements being made in the field of stem cell medicine. Determined to make these advancements available to as many patients as possible, Mr. Novas grew GSCG from humble beginnings to the company’s current status as a key player in promoting point of care regenerative medicine therapies worldwide.
$600 BILLION BOFA..WALL STREET'S MAJOR INVESTMENT BANKS..
..One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025..
Regenerative medicine will dramatically alter the U.S. healthcare industry
..Because of the economic potential of this industry (the worldwide market for regenerative medicine is conservatively estimated to be $500 billion..
An example of some conditions and diseases that could be easily cured by regenerative medicine and their current cost of treatmentt include:
250,000 patients receive heart valves, at a cost of $27 billion annually 950,000 people die of heart disease or stroke, at a cost of $351 billion annually(8) 17 million patients with diabetes, at a cost of $132 billion annually
..By doing so, we can make tissue and organ failure a relic of the past by 2020.
Interagency Federal Working Group on Regenerative Medicine
Chair Howard Zucker, MD, JD Deputy Assistant Secretary for Health U.S. Department of Health and Human Services National Institutes of Health Donna Dean, PhD Colleen Guay-Broder, MPH Eleni Kousvelari, PhD Christine Kelley, PhD John Watson, PhD Josh Zimmerberg, PhD
Food and Drug Administration Charles Durfor, PhD Donald Fink, PhD Joyce Frey, PhD Jesse Goodman, MD Darin Weber, PhD Celia Witten, PhD
The Smart Money Is Piling Into Regenerative Medicine
Progressive Approval Could Be a Game Changer for RM Investing in Regenerative Medicine
The Goldman report discusses Samumed, a private RM company. With $300 million in funding, [b[color=red]]it’s valued at a staggering $12 billion[/color]. Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.
Goldman Sachs defines regenerative medicine as approaches that grow cells or tissue from stem cells, treatments that promote regeneration, or transplants using organs or tissue grown outside the body.
Goldman Sachs highlighted..$12 billion private biotech startup that wants to regenerate hair, skin, bones, and joints, and Unity Biotechnology, which is working on treatments that act on senescent cells.
Money is pouring in to a hot new area of science that could change the way we think about aging
.."We believe companies backed by academic pioneers ... or those with novel platforms ... are likely to garner the largest investments and valuations," the report said.
The Shiller P/E is amore reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
Stem cells are the clearest opportunity to provide humans with a potentially life-saving solution in the future..Furthermore, the combination of private and public healthcare is the subject of current research, as is the development of new solutions and therapies...
Today, stem cells..are routinely used to treat approximately 80 medical conditions including leukaemia, lymphoma, immune disorders and anaemia. However, affordability and accessibility remain a challenge.
Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?
Alzheimer's disease (AD) is the most important neurodegenerative disorder with a global cost worldwide of over $700 billion
Expert opinion: Unsuccessful outcomes in AD therapeutics are attributed to pathogenic misconceptions, erratic procedures in drug development and inappropriate regulations.
..Stem cells harvested here can help patients with sickle-cell disease and leukaemia.
https://www.nature.com/articles/515S14a Treatments for eye diseases are considered among the most promising for stem cells, which have been under study for more than 3 decades. While proponents say all this groundwork is finally coming to fruition, others call progress slow and plodding.
.."I would say the pace of things has been much faster than I would have predicted," says Andy McMahon, PhD, a W.M. Keck provost and university professor at the University of Southern California.
In comparison, Wells says, prescription drugs often take 15 years to progress from research stages to market.
At current rates, by 2025, nearly ¼ of the US GDP will be spent on healthcare. It takes on average 12 years and $359 million to take a new drug from the lab to a patient. Only 5 in 5,000 of these new drugs make it to human testing. From there, only 1 of those 5 is actually approved for human use. And Now, the Good News:
We are in the midst of a (medical) revolution driven by exponential technology: artificial intelligence, sensors, robotics, 3D printing, big data, genomics and stem cells.
Today’s $3.8 trillion dollar healthcare industry is in the deceptive phase of its march towards dematerialization, demonetization and democratization (as I discuss in my A360 Summits).
Stem Cells:
We are now in the earliest stages of stem cell therapy development. Future therapies will be transformative and, frankly, mind-boggling.
Stem cell therapy promises tissue regeneration and renewal – and thus a “cure” for everything from blindness to spinal cord injuries, type 1 diabetes, Parkinson’s disease, Alzheimer’s disease, heart disease, stroke, burns, cancer and osteoarthritis. In 2012, researchers at Cedars-Sinai reported one of the first cases of successful therapeutic stem cell treatment – they used patients’ own stem cells to regenerate heart tissue and undo damage from a heart attack.
Pfizer and Allergan Merge in $160 Billion Deal to Become New Behemoth in the Drug World
What Does Pfizer Have to do with the World of Stem Cells?
Most people would not call Pfizer a stem cell company, much less a cell therapy company, a regenerative medicine company, or even a biotech company. Pfizer is viewed as a “classic and traditional” pharmaceutical company, best known for its blockbuster sales of drugs, such as Lipitor and Viagra. While Pfizer is largely a drug company, the company has expressed periodic interest in the stem cell sector.
Executive Committee and Board Member of the Coral Gables Chamber of Commerce, former President of the Rotary Club of Brickell, current President of BNI Coral Gables, past president of his home owner’s association, and supporter of many fundraisers devoted to the community. Eric also regularly teaches other lawyers for their continuing legal education, presents to The American Immigration Lawyers Association, and more.
Washington College of Law. Juris Doctor (JD) Kogod School of Business. Masters in Business Administration (MBA) Southern Methodist University. Bachelor of Arts (BA). Sigma Chi Fraternity Jesuit College Preparatory School, Dallas
Bar Admissions:
State of New York State of Maryland District of Columbia State of Florida Federal District Court for the Southern District of Florida Federal District Court for Maryland U.S. Tax Court
CLE Lecture: “The New Tax Rules for Mergers and Acquisitions.” June, 2018
..Stem cells are jacks of all trades, capable of alleviatingthe consequences of such diverse pathologies as heart attacks, strokes and cancer. ..In a new study, Yale researchers succeeded in doing so, opening the door to new stem cell-inspired, cell-free treatments for the effects of a heart attack. https://phys.org/news/2019-07-decoding-cells-stem-potential.html
“Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth,” says the US National Institutes of Health. “In many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive
Market cap: $2.09 billion; current share price: $24.25 Market cap: $226.15 Million; current share price: $1.83 Market cap: $161.84 million; current share price: $1.47 Market cap: $267.60 million; current share price: $19.10 Market cap: $392.71 million; current share price: $11.25 Market cap: $64.63 million; current share price: $3.43 Market cap: $54.74 million; current share price: $5.78 Market cap: $11.05 million; current share price: $0.31 Market cap: $29.88 million; current share price: $2.75 Market cap: $28.40 million; current share price: $1.30 https://investingnews.com/daily/life-science-investing/genetics-investing/top-stem-cell-nasdaq/
CONSUMER REPORT..stem cells market. a whole lot of demand
The power to print money. Trillions of dollars – on-demand.[/color]
..For the first time in history - central banks are now funneling trillions of dollars, directly into the stock market.
The Swiss National Bank is on a buying spree – adding hundreds of thousands of shares of Ford, Xcel Energy, Costco, and many other American companies to its portfolio in the last few months.
According to Bloomberg, The Bank of Japan is now the #1 buyer of Japanese stocks. And if their buying binge continues – within a few years, they could own the ENTIRE market! China's Central bank – the world's largest central bank, worth more than $5.4 trillion -- is now a Top 10 shareholder in the biggest, most well-known stocks in Shanghai.
..After receiving a personal invitation from President Susumu Takayangi MD, Global Stem Cells Group and its Korean biotechnology partner, N-Biotek, participated in the 23rd Congress of the International Society of Aesthetic Plastic Surgeons that took place this October in Kyoto.
The Congress brought together an expert panel for a series of lectures and discussions that hope to provide solutions and create new techniques in the coming years to be applied in plastic and reconstructive surgery. Influential scientific and clinical experts stood together and evaluated the state of research and clinical application.
The keynote speaker in the conference was the Nobel Laureate Shinja Yamanaka. Dr Yamanaka won the award on 2012 for his creation of induced pluripotential stem cells. Yamanaka addressed among other things the importance of the regenerative medicine field opening a new frontier for the treatment of chronic degenerative conditions.
..Both companies, as leaders of the industry, launched their new Turnkey Solution, a compact and cohesive laboratory as a concept for physicians’ offices, and the new Progenikine Kit, an enzyme based closed system for isolation of adipose derived stem cells. To learn more, visit the Global Stem Cells Group website, www.stemcellsgroup.com.
..Doctors at St. Jude Children's Research Hospital used Mustang-developed "genetic surgery" to restore the broken immune systems of these eight infants afflicted with the disease. Stansberry Innovations Report editor Christian Olsen explained how this works in a private note on Friday...
First they extracted stem cells from a patient, then used a modified HIV virus to deliver and insert a healthy IL2RN gene into the stem cells, and then infused the modified stem cells back into the patient.
To get the patient ready to accept the changed cells, they were given a low dose of chemotherapy to prime the bone marrow. The bone marrow is what will produce blood cells from the genetically corrected stem cells and... Voila! Healthy immune system.
This may sound like science fiction.But it's not...
Gene therapy and editing is a real and growing trend you will hear about much more over the next several years. More from Christian...
This is real personalized medicine, which is the "Holy Grail." Cells were taken from a patient and used to create the treatment.
There is no doubt we are on the cusp of more of these success stories but, remember, at this stage we (at best) have a curative potential for "bubble boy" disease. There has to be more testing, but the news is incredibly promising.
So, MBIO shot up because it's the lead dog in this treatment tech, since it licensed it to treat patients at St. Jude.
One of the greatest challenges of the 21st century is disease associated with ageing. Cancer, neurodegeneration and heart disease are all major causes of death and have an enormous impact on quality of life.
..Over recent years, a revolution in biology has meant that effective regenerative medicine, using stem cells to replace and repair damaged tissue is now on the horizon. Naturally occurring ‘immortal’ stem cells are present in all tissues of the body and act to replace loss of cells in tissues with rapid turnover, for example in the skin, blood or intestine, or to repair damage as in wound healing.
..The new biotech initiative whose board includes former Apple CEO John Sculley, ex-FDA commissioner Andrew Von Eschenbach and founder of Alphabet’s venture capital arm Bill Maris, is built around the idea that stem cells found in postpartum human placentas are ideal for regenerating damaged and aged tissue
..“There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease,”
The most successful stem cell therapy—bone marrow transplant—has been around for more than 40 years. Johns Hopkins researchers played an integral role in establishing the methods for how bone marrow transplants are done
..Our mission is to find cures for human diseases.
The Harvard community and the greater Boston area are home to the largest concentration of biomedical researchers in the world. This allows our network of over 1,000 scientists, from across Harvard and its eight affiliated hospitals, to advance stem cell biology and translational me
Adimarket, has announced an agreement with biotechnology company Alolotl Biologix ..healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.
Human allograft under FDA regulation 21 CFR Part 1271 ..Immune privileged with anti-inflammatory and anti-bacterial properties
$LAHO..US health..spending increased 5.8% to..USD 3.2 Trillion trillion which is also expected to impel the growth of stem Cell and regenerative medicine market in the North America. U.S. is the prominent market driving the growth in the region.
..North America is slated to account for a leading share of 39.7% by 2024 in the stem cell and regenerative medicine market. The growth in the region can be attributed to presence of well-established healthcare industry along with expanded funding from the governments organizations.
Who Wants To Live Forever?..The Super-Rich, That's Who (And Most Everyone Else)
..Not only do many of the super-rich want immortality, but a good number of them are doing something about it. The likes of Sergey Brin, co-founder of Google, Larry Ellison, Co-founder of Oracle, and investor Peter Thiel are all putting money into ventures that are focused on extending the human life span.
..Hacking our DNA is another approach being taken. Our ability to use stem cells to cure disease is becoming increasingly an opportunity. Very possibly using stem cell technology, as well as modifications to our DNA, can result in significantly longer fruitful lives.
..Global Stem Cells Group Teams With CordónVida Servet Stem Cell Bank and Clinic to Organize the First International Symposium on Stem Cells and Regenerative Medicine
On the immortality of stem cells University of Cologne
Summary: Stem cells are considered to be immortal in culture and, therefore, of great interest for aging research. This immortality is regulated by increased proteostasis, which controls the quality of proteins. A team of researchers found a link between increased proteostasis and immortality of human embryonic stem cells
The cell is the minimal body’s representation, it is the basic unit for the living species where all the vital functions happen such as respiration, nutrition, and reproduction. The STEM CELL is a special cell that normally circulates in the body, responsible for regenerating naturally the deteriorating organs. This treatment seeks for the stem cells to differentiate or become healthy cells from damaged or defective tissue to improve the function of the diseased organ.
Cellgenic Catalogue! $2100.00* · Brand: ADIMarket Cellgenic Pure contains 10 millions of live nucleated cells that exert an anti inflammatory and immunomodulatory effect that aids in optimizing
The cell is the minimal body’s representation, it is the basic unit for the living species where all the vital functions happen such as respiration, nutrition, and reproduction. The STEM CELL is a special cell that normally circulates in the body, responsible for regenerating naturally the deteriorating organs. This treatment seeks for the stem cells to differentiate or become healthy cells from damaged or defective tissue to improve the function of the diseased organ.
http://cellgenic.com/ Cellgenic Catalogue! $2100.00* · Brand: ADIMarket Cellgenic Pure contains 10 millions of live nucleated cells that exert an anti inflammatory and immunomodulatory effect that aids in optimizing $2,382.00 Cellgenic Amniotic Fluid-Human placental Derived
LAHO!..CEO Announces..New Stem Cell Center in Valencia, Spain
..“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.” https://www.otcmarkets.com/stock/LAHO/news/story?e&id=1376239
NASA and Techshot Trying To 3D Print Organs In Space
..Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, announces it will represent CELLLINK 3D Bioprinting Technology in Latin America. CELLINK is the world’s first company biotech company to market bioinks for 3D bioprinting of human organs and tissue. http://www.stemcellsgroup.com/tag/3d-bioprinnting/
3D Bioprinting Market To Reach USD 4.40 Billion
.. rise in geriatric population, technological improvements for manufacturing customized Material Types, and growth in focus on R&D investment. Also, the increase in usage of 3D printing in cosmetic surgeries is anticipated to increase the market growth during the forecast period further.
Global Stem Cells Group CEO Benito Novas is driven by his passion for helping physicians and scientists change the world through stem cell medicine. Dedicated to creating critical organizational systems that ensure success, he is an expert in the field of specialized marketing focused on Biotechnology, Life Sciences, and Healthcare development. http://www.stemcellsgroup.com/management/
Global Stem Cells Group’s Benito Novas Announces Agreement with Clinica Planas
..The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
..Bioheart, Inc. (otcqb:BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico. The two companies have successfully treated their first congestive heart failure patient at the new clinical site last week using Bioheart's AdipoCell (adipose derived stem cells).
Global Stem Cells Group to Host Stem Cells and Regenerative ... ISSCA Physicians looking for new alternatives to improve the quality of life of their patients through emerging regenerative medicine protocols..
“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.”
In opening the new center, the GSCG has signed an agreement with Dra. Laura Maria Caicedo, medical director of the Instituto Valenciano MEDEC (https://medec.es/conoce-medec/#equipoMedico). Dr. Caicedo is a specialist on hair loss with an interest in delivering stem cell based treatments to her patients and others in Valencia.
J. Victor Garcia Gimenez, M.D. is president of Therapeutic Confrontations (CONFTERA), is a specialist in orthopedic surgery and practices cosmetic medicine and surgery, anti-aging medicine, and aesthetic therapies in Barcelona, Spain. http://stemcellcenter.net/centers/spain/barcelona/barcelona-spain/\
Aesthetic Marketing Group Announces the First International Meeting on Marketing in Aesthetic Medicine
GSCG..ISSCA Reaches Agreement with Belgium’s Churchill Aesthetic Center
..The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and... Friday, June 21st 2019, 12:32 PM CDT The innovative new center will provide training in regenerative medicine for doctors located in Belgium and France. ..We look forward to ISSCA’s exciting new partnership with Belgium’s Churchill Aesthetic Center and the possibilities it brings in delivering safe and effective regenerative medicine treatment options to more patients across the globe,” said Benito Novas, CEO of the Global Stem Cells Group.
....The cutting-edge facility will be equipped by Adimarket, LLC, a subsidiary of the Global Stem Cells Group. Adimarket will outfit the center with equipment and supplies designed to not only teach doctors about the latest protocols in regenerative medicine but also to treat patients suffering from degenerative diseases and sports injuries. Physicians training at the facility will have access to the proven expertise of ISSCA’s global network and training protocols. http://www.stemcellsgroup.com/issca-reaches-agreement-with-belgiums-churchill-aesthetic-center/
Daeyong Kim, Ph.D. is an internationally recognized health educator, and CEO of N-Biotek, Inc, a preeminent manufacturer of biomedical and laboratory equipment. N-Biotek is a leader of stem cell technologies, providing solutions for providers worldwide.
..Dr. Zhang is an accomplished scientist, microbiologist and virologist who has worked extensively in the U.S. for the CDC, the National Institutes of Health (NIH) and the US Food and Drug Administration in various research positions, including senior associate at the National Research Center. A Chinese-American, Dr. Zhang received the Award for Scientific Achievement from the FDA
..Al Sears, M.D. often referred to as "America’s #1 anti-aging doctor," is the director of the world renowned Sears Institute for Anti-aging Medicine. Dr. Sears has published 35 books and reports on health and wellness, and has millions of loyal readers in 163 countries. Dr. Sears has been featured on ABC News, CNN and ESPN. He was one of the first specialists to be board-certified by the American Academy of Anti-Aging Medicine (A4M).
Dr. Feinerman offers stem cell treatments for a variety of disorders and diseases. He earned his medical degree from New York Medical College in 1954. Dr. Feinerman is affiliated with Long Island College Hospital in New York and Mayo Clinic in Rochester, Minnesota.
Dr. Feinerman is a member of the Society of Apheresis, Society of Bone Marrow Blood Transplantation, and the International Society for Cellular Therapy, the Society for Cranial Transplantation and Brain Repair and the Society for Cardiac Translational Therapy.
$LAHO GSCG..REPRESENTING 46% MARKET GROWTH IN THERAPY REGENERATION, 3D PRINTING, COSMETIC, MEDICAL DEVICES, PROVIDER CONSULTATION. BOFA ESTIMATES $600 BILLION TARGET, USDHHS CONSERVATIVE ESTIMATE $500 billion AND IMPRESSIVE 7300% VENTURE CAPITAL INVESTMENT GROWTH. GOLDMAN SACH'S, BILLIONAIRES PURING MONEY INTO STEM CELLS..TRILLION DOLLAR LONGEVITY-THERAPY MARKET.. EACH SEGMENT WORTH BILLIONS, EACH DIVISION OF GSCG COULD RUN TO PENNIES..COMBINED?